SWOG clinical trial number
S0020
A PHASE II STUDY OF ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
Closed
Phase
Accrual
16%
Research committees
Leukemia
Treatment
Anti-thymocyte globulin
Eligibility Criteria Expand/Collapse
Morphologically confirmed diagnosis of MDS in one of the following subclassifications: RA, RARS, RAEB and be in one of the following International Prognostic Scoring System (IPSS) risk categories: low, intermediate-1, intermediate-2; no previous BM or SC transplant, no prior chemotherapy for MDS. Patients must have received transfusions of at least 4 units of red blood cells as supportive care for anemia during the 60 days before registration; PS 0-2, HIV negative.
Other Clinical Trials
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302
Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase